Your session is about to expire
← Back to Search
Intraoperative Epidural for Pancreas Surgery
Study Summary
This trial is testing if starting an epidural earlier in surgery can help reduce complications.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am scheduled for surgery to remove part of my pancreas and small intestine.I was excluded after surgery because my disease couldn't be fully removed.I have used long-term pain medication in the last 3 months.I am 18 years or older and can give my consent.I cannot have an epidural according to pain management rules.
- Group 1: Epidural-General Anesthesia
- Group 2: General Anesthesia
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any vacancies in this research project for study participants?
"This specific trial is not currently active, however, it was last updated on 8/8/2022. There are 648 other trials that are presently recruiting patients."
What is the standard course of treatment for Propofol+ Rocuronium+ Fentanyl 2 mcg/kg+ Inhalational Agent, Bupivacaine 0.125% + Fentanyl 5 mcg/ml?
"Propofol+ Rocuronium+ Fentanyl 2 mcg/kg+ Inhalational Agent, Bupivacaine 0.125% + Fentanyl 5 mcg/ml is most often used for the treatment of permphigus; however, it can also be an effective medication for acute nonspecific tenosynovitis, general anesthesia, and lupus erythematosus cell."
Are there any other instances of research teams testing this mix of drugs on patients?
"At this moment, there are 244 ongoing clinical trials related to the use of Propofol+ Rocuronium+ Fentanyl 2 mcg/kg+ Inhalational Agent, Bupivacaine 0.125% + Fentanyl 5 mcg/ml for medical purposes. Out of these 244 trials, 43 are currently in Phase 3. Many of the clinical trials for Propofol+ Rocuronium+ Fentanyl 2 mcg/kg+ Inhalational Agent, Bupivacaine 0.125% + Fentanyl 5 mcg/ml are taking place in Germantown, Tennessee; however,"
How many people are currently enrolled in this clinical trial?
"Unfortunately, this study is not recruiting new participants at the moment. It was originally posted on January 30th 2018 and updated for the last time on August 8th 2022. However, there are 404 other trials actively enrolling patients with malignant neoplasm of pancreas and 244 trials for Propofol+ Rocuronium+ Fentanyl 2 mcg/kg+ Inhalational Agent, Bupivacaine 0.125% + Fentanyl 5 mcg/ml that you could explore."
What is the FDA's opinion on using Propofol+ Rocuronium+ Fentanyl 2 mcg/kg+ Inhalational Agent, Bupivacaine 0.125% + Fentanyl 5 mcg/ml?
"Given that this is a Phase 3 trial with supporting efficacy data and multiple rounds of safety data, our team has estimated the safety of Propofol+ Rocuronium+ Fentanyl 2 mcg/kg+ Inhalational Agent, Bupivacaine 0.125% + Fentanyl 5 mcg/ml to be a 3 on our scale."
Share this study with friends
Copy Link
Messenger